Smith, Kristen M.
Amgen (United States)
2 papers on CoChatORCID 0000-0003-0960-0937
Most cited papers
- Verified
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 125
- Verified
Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Falchook, G. S., McKean, M., Kelly, W. K., Patel, M. R., Bupathi, M., Liaw, B. C.-H., Garmezy, B., Vuu, I., Smith, K., Gokani, P., et al. (2024) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free